


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF THE FIRST GENERIC
“TULOButEROL PATCHES”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the “Tulobuterol Patches” (trade name: Deruituo (德瑞妥)) developed by the Group has obtained approval for marketing from the National Medical Products Administration of China for relieving symptoms such as dyspnoea caused by bronchial asthma, acute bronchitis, chronic bronchitis, emphysema and other obstructive airway diseases. This is the first domestically produced topical patch for obstructive airway diseases approved for marketing.

Tulobuterol patch acts on β 2-receptors in bronchial smooth muscle and plays a role in improving pulmonary function, promoting tracheal ciliary movement and suppressing coughing through dilating the bronchial tubes and relaxing the airway muscles. Compared with traditional drugs for treatment of asthma, tulobuterol patch is administered systemically through transdermal administration, thereby avoiding the hepatic first-pass effect, reducing gastrointestinal irritation and maintaining stable plasma concentrations, thus controlling asthma symptoms more effectively while providing a convenient and safe solution for the long-term treatment of patients with asthma, acute and chronic bronchitis, emphysema, and other obstructive airway diseases.

Tulobuterol patch is suitable for a wide range of population and can be used by children aged half a year and above. Compared with oral and inhaled formulations, tulobuterol patch is easy and convenient in terms of administration, thus solving the problem of difficulties in administering drugs to children and reducing the errors in administration of drugs caused by improper handling. Deruituo breaks the monopoly of imported drugs and will substantially relieve the tension of asthma medication supply to children in China.

As a leading enterprise of transdermal formulations in China, the Group has a pipeline of more than ten kinds of patches under development covering analgesia, Parkinson's disease, insomnia and other areas. Currently, the Group possesses Flurbiprofen Cataplasms, Lidocaine Cataplasms, Loxoprofen Sodium Cataplasms, Rivastigmine Transdermal Patch and other products which have obtained approval for marketing. The Group will accelerate the development and iteration of its patch products in order to further enrich its product pipeline and bring wellness to more people with its health technology.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 7 February 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.